Authors: Federico Boggio, Alessandro Ciavarella, Sara Arcudi, Roberta Gualtierotti, Raffaella Rossio, Francesco Tafuri, Andrea Artoni & Flora Peyvandi Abstract Thrombocytopenia is a common feature of antiphospholipid syndrome (APS) and rarely requires treatment.

Authors: Jozélio Freire de Carvalho & Carlos Ewerton Maia Rodrigues Abstract Introduction Acute myocardial infarct/angina (AMI-A) is a possible complication in primary antiphospholipid syndrome (pAPS) patients.

Evidence-based recommendations for the management of antiphospholipid syndrome in adult patients have been issued by EULAR.

Research has revealed factors associated with complete remission in patients with systemic lupus erythematosus, including lack of renal involvement and antiphospholipid syndrome, White ethnicity, and older age at diagnosis.

These included antiphospholipid syndrome, and higher urinary protein/creatinine ratio, SLEDAI , and estimated glomerular filtration rate, as well as lower complement component 3, lower serum albumin and hemoglobin levels, and lower leucocyte, lymphocyte, and eosinophil counts. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group Ann Rheum Dis 2022; doi:10.1136/annrheumdis-2022-222435

EULAR has issued recommendations for managing cardiovascular risk in people with antiphospholipid syndrome, gout, mixed connective tissue disease, myositis, Sjögren’s syndrome, systemic lupus erythematosus, systemic sclerosis, or vasculitis.

A monthly selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

Study findings suggest that mRNA COVID-19 vaccines have a favorable short-term safety profile in people with antiphospholipid antibodies.

3–9 November: Keep up with the latest news and interviews from the conference.

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

5 – 9 November: Preview the conference with session recommendations and updates on upcoming coverage.

How will the FAST trial results impact regulatory guidance & clinical practice?

They also report that the prevalence of conventional and non-conventional antiphospholipid antibodies (APA) was low (≤10.5%) in both groups, with few significant differences between them.

As reported in a correspondence to The Lancet Rheumatology , there were six cases of systemic rheumatic disease in the COVID-19 group – one each of seronegative inflammatory arthritis, giant cell arteritis, dermatomyositis, antiphospholipid syndrome, seronegative rheumatoid arthritis, and primary Sjögren’s syndrome.

Experts discuss the increasing use of telemedicine in rheumatology during the COVID-19 pandemic.

Of these, eight had systemic lupus erythematosus (three with co-existing antiphospholipid syndrome), three had rheumatoid arthritis, one had inflammatory arthritis, one spondyloarthropathy, and one myositis.

In the case of a presumed thrombotic mechanism associated with aPL (antiphospholipid syndrome [APS]), anticoagulation therapy is recommended for secondary prevention.

Maria Tektonidou More on this topic: News story |  Guidelines for management of antiphospholipid syndrome Update of the EULAR recommendations large vessel vasculitis management.  

They point out that SLE patients are at risk for comorbidities such as antiphospholipid syndrome, infections, and cardiovascular disease, and recommend assessment of these comorbidities, as well as preventive strategies.